Novo Nordisk a S
NVONYSECIK 353278HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $bn | 141Revenue, FY2021, twelve months to 2021-12-31DKK 140.80bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-01-31, accession 0001628280-24-002635.Report this figure | 177Revenue, FY2022, twelve months to 2022-12-31DKK 176.95bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-02-05, accession 0001628280-25-003920.Report this figure | 232Revenue, FY2023, twelve months to 2023-12-31DKK 232.26bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 290Revenue, FY2024, twelve months to 2024-12-31DKK 290.40bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 309Revenue, FY2025, twelve months to 2025-12-31DKK 309.06bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | |
| Gross margin | % | 83.2%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: DKK 117.14bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2024-01-31, accession 0001628280-24-002635.Revenue: DKK 140.80bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-01-31, accession 0001628280-24-002635.Report this figure | 83.9%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: DKK 148.51bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2025-02-05, accession 0001628280-25-003920.Revenue: DKK 176.95bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-02-05, accession 0001628280-25-003920.Report this figure | 84.6%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: DKK 196.50bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 232.26bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 84.7%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: DKK 245.88bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 290.40bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 81.0%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: DKK 250.28bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 309.06bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | |
| Operating margin | % | 41.7%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: DKK 58.64bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-01-31, accession 0001628280-24-002635.Revenue: DKK 140.80bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-01-31, accession 0001628280-24-002635.Report this figure | 42.3%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: DKK 74.81bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-02-05, accession 0001628280-25-003920.Revenue: DKK 176.95bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-02-05, accession 0001628280-25-003920.Report this figure | 44.2%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: DKK 102.57bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 232.26bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 44.2%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: DKK 128.34bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 290.40bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 41.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: DKK 127.66bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 309.06bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | |
| Net margin | % | 33.9%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: DKK 47.76bn. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2024-01-31, accession 0001628280-24-002635.Revenue: DKK 140.80bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-01-31, accession 0001628280-24-002635.Report this figure | 31.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: DKK 55.52bn. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2025-02-05, accession 0001628280-25-003920.Revenue: DKK 176.95bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-02-05, accession 0001628280-25-003920.Report this figure | 36.0%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: DKK 83.68bn. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 232.26bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 34.8%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: DKK 100.99bn. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 290.40bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 33.1%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: DKK 102.43bn. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2026-02-04, accession 0000353278-26-000012.Revenue: DKK 309.06bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | |
| Diluted EPS | $ per share | 10.37Diluted EPS, FY2021, twelve months to 2021-12-31DKK 10.37 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-01-31, accession 0001628280-24-002635.Report this figure | 12.22Diluted EPS, FY2022, twelve months to 2022-12-31DKK 12.22 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-02-05, accession 0001628280-25-003920.Report this figure | 18.62Diluted EPS, FY2023, twelve months to 2023-12-31DKK 18.62 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 22.63Diluted EPS, FY2024, twelve months to 2024-12-31DKK 22.63 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 23.03Diluted EPS, FY2025, twelve months to 2025-12-31DKK 23.03 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | |
| Free cash flow | $bn | 48.7Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: DKK 55.00bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-01-31, accession 0001628280-24-002635.Capital expenditure: DKK 6.33bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-01-31, accession 0001628280-24-002635.Report this figure | 66.7Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: DKK 78.89bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-02-05, accession 0001628280-25-003920.Capital expenditure: DKK 12.15bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-02-05, accession 0001628280-25-003920.Report this figure | 83.1Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: DKK 108.91bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Capital expenditure: DKK 25.81bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 73.8Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: DKK 120.97bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Capital expenditure: DKK 47.16bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure | 59.0Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: DKK 119.10bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Capital expenditure: DKK 60.14bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-02-04, accession 0000353278-26-000012.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Dodge & Cox | 2026-06-30 | $977.8m | 20,397,110 | Added+1,063,360 | |
| LOOMIS SAYLES & CO L P | 2026-06-30 | $891.4m | 18,594,352 | Added+1,577,037 | |
| FRANKLIN RESOURCES INC | 2026-06-30 | $625.2m | 13,041,109 | Reduced−3,042,370 | |
| PeakShares LLC | 2026-06-30 | $606.1m | 12,642 | Unchanged | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-06-30 | $575.7m | 12,009,200 | Call | Added+7,410,300 |
| MORGAN STANLEY | 2026-06-30 | $559.0m | 11,659,869 | Added+790,669 | |
| BANK OF AMERICA CORP /DE/ | 2026-06-30 | $535.8m | 11,176,712 | Added+407,013 | |
| Capital International Investors | 2026-06-30 | $467.6m | 9,721,180 | Reduced−2,074,670 | |
| FOLKETRYGDFONDET | 2026-06-30 | $456.5m | 9,522,383 | Added+441,563 | |
| GOLDMAN SACHS GROUP INC | 2026-06-30 | $440.1m | 9,180,490 | Added+4,059,453 |
Recent filings
All 1,668 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2612:33 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-26 | 0001171843-26-006813 |
| 2026-10-1908:31 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-19 | 0001171843-26-006685 |
| 2026-10-1306:15 ET | 6-K | Report of a foreign private issuerPeriod 2023-10-12 | 0001171843-26-006585 |
| 2026-10-0608:11 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-05 | 0001171843-26-006440 |
| 2026-10-0517:53 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-02 | 0001171843-26-006374 |
| 2026-09-2811:23 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-28 | 0001171843-26-006248 |
| 2026-09-2111:11 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-21 | 0001171843-26-006128 |
| 2026-09-1712:21 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-17 | 0001171843-26-006088 |
| 2026-09-1506:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-14 | 0001171843-26-006038 |
| 2026-09-0906:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-07 | 0001171843-26-005925 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Feb 4, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 353278
- Tickers
- NVO, NONOF
- Exchange
- NYSE
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- not reported
- Filer category
- Large accelerated filer
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 12:35 ET. Listed shows no prices and gives no investment advice.